Moreover, NLRC5 silencing improved the chemosensitivity of NSCLC-resistant cells to carboplatin, which relied on the activation of PI3K/AKT regulated by CEACAM1. This evidence concerns the gene CEACAM1 and non-small cell lung carcinoma.